In mice, 24-hour immune window shapes viral survival
At Hokkaido University, genetically identical mice met the same lethal virus in the same controlled environment. Some survived. Others did not. The difference appeared in the first 24 hours: mice that survived produced a rapid burst of type I interferon, including IFNβ, an immune signal that helps coordinate the antiviral response.
The team studied vesicular stomatitis virus, or VSV, and found that the early interferon signal activated a distinct group of neutrophils, immune cells involved in inflammation. These neutrophils carried the surface marker ICAM1 and showed heightened inflammatory signaling alongside an enhanced antiviral profile. The result gives biological meaning to variation that might otherwise be dismissed as experimental noise, lead author Tomohiko Okazaki said.
Timing was central. When the researchers blocked type I interferon during the first 24 hours after infection, most of the mice died. Blocking the signal two days after infection had little effect. In the study, the opening day functioned as a narrow checkpoint: an effective antiviral response was established early, or the animals were far less likely to survive.
So what does this change, concretely? If the same mechanism operates in humans, treatments that strengthen or mimic this early immune response could potentially improve outcomes in severe viral infections. That could offer a way to account for some uneven outcomes that age and underlying medical conditions do not fully explain. For now, the finding is a laboratory result in mice, and no human treatment or clinical benefit has been demonstrated.
The study, published in iScience, does not show that identical infections will produce identical outcomes in people, nor that an interferon-based intervention would be safe or effective. It identifies a candidate mechanism and a precise early window for future research: whether ICAM1-positive neutrophils and type I interferon dynamics play a comparable role in human viral disease.
Kommentare
Der Thread wird geladen…
Melden Sie sich an, um einen Kommentar zu schreiben. Anmelden